AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Many of you are probably options traders. Several of our analysts at TheStreet Pro are, and when times are risky, they will often suggest options a...

Three Options Trades That Could Return Up To 841%

Abbvie ($ABBV) announced an update on their ongoing clinical study. The AbbVie (ABBV) study “Observational Prospective Study to Evaluate Effectiven...

AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch

Scotiabank analyst Louise Chen maintained a Buy rating on AbbVie today and set a price target of $280.00. According to TipRanks, Chen is a 4-star a...

AbbVie (ABBV) Gets a Buy from Scotiabank

Analysts fell to the sidelines weighing in on AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF) and Hims & Hers Health (HIMS) with neutral ratings, i...

Analysts’ Top Healthcare Picks: AbbVie (ABBV), Takeda Pharmaceutical Co (TKPHF)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a real world study called “Prospective Observationa...

AbbVie’s Real-World Migraine Study Nears Data Release: What Investors Should Watch

The Schwab U.S. Dividend Equity ETF ($SCHD) has been one of the strongest performers of 2026, outgaining the S&P 500 ($SPX) by over 12% so far this...

SCHD ETF Slips Ahead of Portfolio Reshuffle — UNH, QCOM In; HAL, VLO Out

AbbVie ( ($ABBV) ) has fallen by -7.40%. Read on to learn why. AbbVie shares fell 7.40% over the past week, even as Wall Street analysts largely st...

AbbVie Stock Slides as Insider Selling Spooks Investors

Abbvie ($ABBV) announced an update on their ongoing clinical study. The phase 1 study, officially titled “A Phase 1 Study in Healthy Subjects to As...

AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment

AbbVie ($ABBV) stock trades at a deep discount for a pharma company growing this fast. The market still seems anchored to an old narrative: that Ab...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABBV	$212.40	+0.38%	4.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABBV	$212.40	+0.4%	4.47M
3
4
5
6

ABBV

ABBV

Get AbbVie Inc. Data in Excel

Get AbbVie Inc. Data in Excel